EICHOR
● Completed
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
Condition: Hereditary Angioedema · Sponsor: CSL Behring
About this study
This study is designed to evaluate the safety after switching to garadacimab from another prophylactic hereditary angioedema (HAE) treatment (marketed kallikrein \[KK\] inhibitor or plasma-derived C1-esterase inhibitor \[pdC1INH\]prophylactic) when administered once monthly for approximately 3 months in participants aged greater than or equal to (\>=) 12 years with HAE.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (11)
| Research Solutions of Arizona | Litchfield Park, Arizona, United States | — |
| Allergy and Asthma Clinic of Northwest Arkansas | Bentonville, Arkansas, United States | — |
| Donald Levy M.D. | Orange, California, United States | — |
| Raffi Tachdjian MD, Inc. | Santa Monica, California, United States | — |
| Bernstein Clinical Research Center, LLC | Cincinnati, Ohio, United States | — |
| Chronicle Bio | West Valley City, Utah, United States | — |
| McMaster University-Hamilton | Hamilton, Ontario, Canada | — |
| Montreal Clinical Research Institute | Montreal, Quebec, Canada | — |
| Clinique Spécialisée en Allergie de la Capitale | Québec, Canada | — |
| HZRM Hämophilie Zentrum Rhein Main GmbH | Frankfurt, Germany | — |
| Hautklinik und Poliklinik der Universitätsklinik Mainz | Mainz, Germany | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06806657